Down Under deal for new drugs

Two new therapies are set to reach Australian shores under an expanded deal between Specialised Therapeutics (ST) and Incyte Biosciences.

The expanded agreement will see CSF-1R-blocking antibody Niktimvo and PD-1 inhibitor Zynyz added to the current partnered portfolio of Minjuvi and Pemazyre.

Niktimvo has already been granted a priority review designation by the TGA for the treatment of chronic graft versus host disease while Zynyz has received orphan status in Merkel cell carcinoma plus a priority review designation in combination with carboplatin and paclitaxel for the first-line treatment of adults with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal.